PSH

• LONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for the company’s Hemophilia A program.
• The FDA grants orphan designation, also referred to as orphan status, to therapies intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S.
• This designation provides certain benefits, including tax credits for qualified clinical testing, waiver or partial payment of FDA application fees and seven years of market exclusivity, if approved.
• Separately, rare pediatric disease designations are granted for rare diseases that primarily affect children under 18 years old with recipients of this designation being awarded a priority review voucher, upon approval.

Any person wishing to attend must be an existing PSH shareholder or bondholder at the time of the presentation. A livestream of the event will also be available. Additional eligibility and registration details are available at www.pershingsquareholdings.com .

• The following summarizes key advancements presented:
  The final conformal coating composition exhibits significantly improved cell compatibility and overall biocompatibility, representing evolution across years of process development work and preclinical testing.
• The final conformal coated product was purified using a process to contain 98% conformal coated islets and only 2% empty capsules.
• “We have made significant advancements in the evolution of the conformal coating technology in our collaboration with Sernova and are confident we have the final formulation.
• “Our goal is to continue to drive this technology ahead and ultimately bring a local immune-protected cell product into the clinic combined with the Sernova Cell Pouch and iPSC islet-like clusters.”

• WESTERLY, R.I., Oct. 18, 2023 /PRNewswire/ -- The Washington Trust Company ("Washington Trust") today announced a commitment totaling $50,000 to support Crossroads Rhode Island's Roads to Home Capital Campaign.
• The donation, which will be paid over five years, will help Crossroads develop more than 300 affordable permanent supportive housing (PSH) apartments in Providence.
• "Through their leadership, expertise, and experience, Crossroads plays a critical role in addressing homelessness in Rhode Island," says Rolando Lora, Executive Vice President, Chief Retail Lending Officer and Director of Community Lending.
• "We know affordable housing opportunities, coupled with programs to support mental health, physical health, and workforce development, is the solution to ending homelessness," says Karen Santilli, CEO of Crossroads Rhode Island.